Biotransformation of diazepam in a clinically relevant flat membrane bioreactor model using primary porcine hepatocytes

Fundamental and Clinical Pharmacology

Volumn 25, Issue 3, 2011, Pages 343-353

  Maringka, Michael ^a,b   Giri, Shibashish ^a   Nieber, Karen ^a   Acikgöz, Ali ^a   Bader, Augustinus ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Diakoniekrankenhaus Henriettenstiftung ^*  (Germany)

Author keywords

Acute liver patients; Bioartificial liver supports (BAL); Flat membrane bioreactor (FMB); Human plasma; Primary porcine hepatocyte; SF 3 medium

Indexed keywords

DIAZEPAM; DRUG METABOLITE; NORDAZEPAM; OXAZEPAM; TEMAZEPAM;

ANIMAL CELL; ARTICLE; BIOARTIFICIAL LIVER; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CLEARANCE; DRUG ELIMINATION; DRUG TRANSFORMATION; HUMAN; LIVER CELL; MEMBRANE REACTOR; MODEL; NONHUMAN; PRIORITY JOURNAL; SWINE;

ADULT; ANIMALS; BIOREACTORS; BIOTRANSFORMATION; CELLS, CULTURED; CULTURE MEDIA; CULTURE MEDIA, SERUM-FREE; DIAZEPAM; FEMALE; HEPATOCYTES; HUMANS; LIVER, ARTIFICIAL; MALE; METABOLIC DETOXICATION, DRUG; NORDAZEPAM; OXAZEPAM; SWINE; TEMAZEPAM; YOUNG ADULT;

EID: 79954626171     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00857.x     Document Type: Article

References (46)

1. Basile A.S., Hughes R., Harrison P.M. et al. Elevated brain concentrations of 1, 4-benzodiazepines in fulminant hepatic failure. N. Engl. J. Med. (1991) 325 473-478.
2. Basile A.S., Jones E.A. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology (1997) 25 1303-1305.
3. Chen L., Peimin F., Jinghua W., Ling L., Dong Z. Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus. J. Clin. Neurosci. (2009) 16 524-526.
4. D'Mello D., Mehta D., Pereira J., Rao C.V. A toxicity study of simultaneous administration of Tamoxifen and Diazepam to female Wistar rats. Exp. Toxicol. Pathol. (1999) 6 549-553.
5. Tecottl L.H. Designer genes and anti-anxiety drugs. Nat. Neurosci. (2000) 3 529-530.
6. A receptors via two distinct and separable mechanisms. Nat. Neurosci. (2000) 3 1274-1281.
7. Strain A.J., Neuberger J.M. A bioartificial liver state of art. Science (2002) 295 1005-1009.
8. Kern A., Bader A., Pichlmayr R., Sewing K.F. Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem. Pharmacol. (1997) 54 761-772.
9. FDA (Food and Drug Administration), Centre for Drug Evaluation and Research. August, 2005. Guidance for Industry, Impurities in Drug Product. Revision I, .
10. Claudia. R., Ballauff A., Lange R., Erhard J. Heterotopic auxiliary liver transplantation in a 3year old boy with acute liver failure and aplastic anemia. Transplantation (1997) 64 658-660.
11. Bader A., Knop E., Böker K. et al. A novel bioreactor design for in vitro reconstruction of in vivo liver characteristics. Artif. Organs (1995) 19 368-374.
12. Bader A., Knop E., Fruhauf N. et al. Reconstruction of liver tissue in vitro: geometry of characteristic flat bed, hollow fiber, and spouted bed bioreactors with reference to the in vivo liver. Artif. Organs (1995) 19 941-950.
13. Bader A., Knop E., Böker K.H.W. et al. Tacrolimus (FK 506) metabolism in primary rat hepatocytes depends on extracellular matrix geometry. Naunyn Schmiedebergs Arch. Pharmacol. (1996) 353 461-473.
14. Bader A., Knop E., Kern A. et al. 3-D coculture of hepatic sinusoidal cells with primary hepatocytes-Design of an organotypical model. Exp. Cell Res. (1996) 226 223-233.
15. Bader A., Zech K., Crome O., Christians U., Pichlmayr R., Sewing K.F. Use of organotypical cultures of primary hepatocytes to analyze drug biotransformation in man and animals. Xenobiotica (1994) 24 623-633.
16. DeBartolo L., Jarosch v., Schweder G., Haverich A., Bader A. A novel full-scale flat membrane bioreactor utilizing porcine hepatocytes: cell viability and tissue-specific functions. Biotechnol. Prog. (2000) 16 102-108.
17. Bader A., DeBartolo L., Haverich A. High level benzodiazepine and ammonia clearance by flat membrane bioreactors with porcine liver cells. J. Biotechnol. (2000) 25 95-105.
18. De Bartolo L., Bader A. Development of a hybrid liver-support device. Minim. Invasive Ther. Allied Technol. (2002) 11 123-134.
19. Washizu J., Berthiaume F., Chan C., Tompkins R.G., Toner M., Yarmush M.L. Optimization of rat hepatocyte culture in citrated human plasma. J. Surg. Res. (2000) 93 237-246.
20. Rocker D., Hesse F., Bader A., Wagner R. Intracellular Nucleotide Pools and Ratios as Tools for Monitoring Dedifferentiation of Primary Porcine Hepatocytes in Culture. Cytotechnology (2006) 51 119-132.
21. Knop E., Bader A., Böker K., Pichlmayr R., Sewing K.F. Ultrastructural and functional differentiation of hepatocytes under long-term culture conditions. Anat. Rec. (1995) 242 337-349.
22. Bader A., Frühauf N., Tiedge M. et al. Enhanced oxygen delivery reverses anaerobic metabolic states in prolonged sandwich rat hepatocyte culture. Exp. Cell Res. (1999) 246 221-232.
23. Elsdale T., Bard J. Collagen substrata for studies on cell behaviour. J. Cell Biol. (1972) 54 626-637.
24. Dunn J.C., Yarmush M.L., Koebe H.G., Tompkins R.G. Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J. (1989) 3 174-177.
25. Maringka M., Giri S., Bader A. Preclinical characterization of primary porcine hepatocytes in a clinically relevant flat membrane bioreactor. Biomaterials (2010) 31 156-172.
26. Acikgöz A., Karim N., Giri S., Schmidt-Heck W., Bader A. Two compartment model of diazepam biotransformation in an organotypical culture of primary human hepatocytes. Toxicol. Appl. Pharmacol. (2009) 234 179-191.
27. Di Nicuolo G., van de Kerkhove M.P., Hoekstra R. No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver. Xenotransplantation (2005) 12 286-292.
28. Hermida-Prieto M., Domenech N., Moscoso I. et al. Lack of Cross-Species Transmission of Porcine Endogenous Retrovirus (PERV) to Transplant Recipients and Abattoir Workers in Contact With Pigs. Transplantation (2007) 84 548-550.
29. Wang H.H., Wang Y.J., Liu H.L. et al. Detection of PERV by polymerase chain reaction and its safety in bioartificial liver support system. World J. Gastroenterol. (2006) 12 1287-1291.
30. Irgang M., Sauer I.M., Karlas A. et al. Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. J. Clin. Virol. (2003) 28 141-154.
31. Levy M.F., Argaw T., Wilson C.A. et al. No evidence of PERV infection in healthcare workers exposed to transgenic porcine liver extracorporeal support. Xenotransplantation (2007) 14 309-315.
32. Sauer I.M., Kardassis D., Zeillinger K. et al. Clinical extracorporeal hybrid liver support-phase I study with primary porcine liver cells. Xenotransplantation (2003) 10 460-469.
33. Van de Kerkhove M.P., Di Florio E., Scuderi V. et al. Bridging a Patient with Acute Liver Failure to Liver Transplantation by the AMC-Bioartificial Liver. Cell Transplant. (2003) 12 563-568.
34. Langsch A., Giri S., Acikgöz A. et al. Interspecies difference in liver specific functions and biotransformation of testosterone of primary rat, porcine and human hepatocyte in an organotypical sandwich culture. Toxicol. Lett. (2009) 188 173-179.
35. Fruhauf N.R., Oldhafer K.J., Holtje M. et al. A bioartificial liver support system using primary hepatocytes: a preclinical study in a new porcine hepatectomy model. Surgery (2004) 136 47-56.
36. Catapano G., De Bartolo L., Lombardi C.P., Drioli E. The effect of oxygen transport resistances on the viability and functions of isolated rat hepatocytes. Int. J. Artif. Organs (1996) 19 61-71.
37. Sullivan J.P., Harris D.R., Palmer A.F. Convection and hemoglobin-based oxygen carrier enhanced oxygen transport in a hepatic hollow fiber bioreactor. Artif. Cells Blood Substit. Immobil. Biotechnol. (2008) 36 386-402.
38. Chu X.H., Shi X.L., Feng Z.Q. et al. In vitro evaluation of a multi-layer radial-flow bioreactor based on galactosylated chitosan nanofiber scaffolds. Biomaterials (2009) 30 4533-4538.
39. Jasmund I., Bader A. Bioreactor developments for Tissue Engineering Applications by the example of the bioartificial liver. Adv. Biochem. Éng. Biotechnol. (2002) 74 100-108.
40. Bader A., Rinkes I.H., Closs E.I. A stable long-term hepatocyte culture system for studies of physiologic processes: cytokine stimulation of the acute phase response in rat and human hepatocytes. Biotechnol. Prog. (1992) 8 219-225.
41. Fahrig R., Rupp M., Steinkamp-Zucht A., Bader A. Use of primary rat and human hepatocyte sandwich cultures for activation of indirect carcinogens: monitoring of DNA strand breaks and gene mutations in co-cultured cells. Toxicol. In Vitro (1998) 12 431-444.
42. Wessman S.J., Levings R.L. Benefits and risks due to animal serum used in cell culture production. Dev. Biol. Stand. (1999) 99 3-8.
43. Sandstrom C., Miller W., Papousakis E. Revew: serum-free media for culture of primitive and mature hematopoietic cells. Biotechnol. Bioeng. (1993) 43 706-733.
44. Dunn J.C., Tompkins R.G., Yarmush M.L. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol. Prog. (1991) 7 237-245.
45. Dunn J.C., Tompkins R.G., Yarmush M.L. Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation. J. Cell Biol. (1992) 116 1043-1053.
46. Berthiaume F., Moghe P.V., Toner M., Yarmush M.L. Effect of extracellular matrix topology on cell structure, function, and physiological responsiveness: hepatocytes cultured in a sandwich configuration. FASEB J. (1996) 10 1471-1484.